Results 211 to 220 of about 310,541 (331)
Identification of novel neutralizing determinants for protection against HCV
Identification of novel neutralizing determinants for protection against hepatitis C virus. Abstract Background and Aims HCV evasion of neutralizing antibodies (nAb) results in viral persistence and poses challenges to the development of an urgently needed vaccine.
Garazi P. Alzua +12 more
wiley +1 more source
HMBOX1 inhibits hepatocellular carcinoma progression via PTPN1 mediated AKT1 phosphorylation. [PDF]
Zhang C +6 more
europepmc +1 more source
ABSTRACT Aim To examine the significance of portal vein tumor thrombus (PVTT) as a prognostic factor for patients with pancreatic ductal adenocarcinoma (PDAC) treated with chemoradiotherapy (CRT) followed by surgery. Methods The study retrospectively examined 313 patients with borderline resectable (BR) or locally advanced (LA) PDAC who underwent CRT ...
Aoi Hayasaki +9 more
wiley +1 more source
Impact of Prior Treatment History on Recurrence After Complete Response to Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma. [PDF]
Nakabori T +11 more
europepmc +1 more source
Exosomes are emerging as powerful biomarkers for disease diagnosis and monitoring. This review highlights the integration of surface‐enhanced Raman spectroscopy with artificial intelligence to enhance molecular fingerprinting of exosomes. Machine learning and deep learning techniques improve spectral interpretation, enabling accurate classification of ...
Munevver Akdeniz +2 more
wiley +1 more source
Melanoma antigen genes A1 and A3 as predictors of treatment response and survival in HCV-associated hepatocellular carcinoma: a prospective study. [PDF]
Elgamal H +6 more
europepmc +1 more source
850f Anti-NASH Effects of Solithromycin in NASH-HCC Mouse Model
Prabhavathi Fernandes +3 more
openalex +1 more source
This study introduces a tree‐based machine learning approach to accelerate USP8 inhibitor discovery. The best‐performing model identified 100 high‐confidence repurposable compounds, half already approved or in clinical trials, and uncovered novel scaffolds not previously studied. These findings offer a solid foundation for rapid experimental follow‐up,
Yik Kwong Ng +4 more
wiley +1 more source
<p>Converting 'cold' to 'hot' hepatocellular carcinoma for improved immunotherapy (Review)</p>. [PDF]
Hsieh CH, Chuang PC.
europepmc +1 more source

